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Abstract
Background: CT-P13 (Remsima®, Inflectra®) is a biosimilar of the infliximab reference product (RP; Remicade®). The
aim of this study was to compare the 54-week efficacy, immunogenicity, safety, pharmacokinetics (PK) and
pharmacodynamics (PD) of CT-P13 and RP in patients with active rheumatoid arthritis (RA).
Methods: In this multinational phase III double-blind study, patients with active RA and an inadequate response to
methotrexate (MTX) were randomized (1:1) to receive CT-P13 (3 mg/kg) or RP (3 mg/kg) at weeks 0, 2, 6 and then
every 8 weeks to week 54 in combination with MTX (12.5–25 mg/week). Efficacy endpoints included American
College of Rheumatology (ACR)20, ACR50 and ACR70 response rates, Disease Activity Score in 28 joints (DAS28),
Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), European League Against Rheumatism
(EULAR) response rates, patient-reported outcomes and joint damage progression. Immunogenicity, safety and PK/
PD outcomes were also assessed.
Results: Of 606 randomized patients, 455 (CT-P13 233, RP 222) were treated up to week 54. At week 54, ACR20
response rate was highly similar between groups (CT-P13 74.7 %, RP 71.3 %). ACR50 and ACR70 response rates were
also comparable between groups (CT-P13 43.6 % and 21.3 %, respectively; RP 43.1 % and 19.9 %, respectively).
DAS28, SDAI and CDAI decreased from baseline to week 54 to a similar extent with CT-P13 and RP. Radiographic
progression measured by Sharp scores as modified by van der Heijde was also comparable. With both treatments,
patient assessments of pain, disease activity and physical ability, as well as mean scores on the Medical Outcomes
Study Short Form Health Survey (SF-36), improved markedly at week 14 and remained stable thereafter up to week
54. The proportion of patients positive for antidrug antibodies at week 54 was similar between the two groups: 41.1
% and 36.0 % with CT-P13 and RP, respectively. CT-P13 was well tolerated and had a similar safety profile to RP. PK/
PD results were also comparable between CT-P13 and RP.
Conclusions: CT-P13 and RP were comparable in terms of efficacy (including radiographic progression),
immunogenicity and PK/PD up to week 54. The safety profile of CT-P13 was also similar to that of RP.
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Background
Infliximab is a chimeric, anti-tumor necrosis factor
(TNF) monoclonal antibody proven to be effective in pa-
tients with active rheumatoid arthritis (RA) not respond-
ing to methotrexate (MTX) [1, 2]. Over the past 15
years, the introduction of infliximab and other biologics
has led to dramatic improvements in the management of
RA, particularly in terms of enabling patients to achieve
better outcomes [3]. However, there is an imbalance in
the availability and affordability of these biologics world-
wide due to their high costs [4, 5].
Some biologics, including infliximab, are at the end of
their patent period. This fact, together with the high
costs of these drugs, has prompted the recent develop-
ment of biosimilar drugs. Biosimilars are highly similar
to already approved innovator or “reference” biologics in
terms of structure, efficacy, safety and quality [6, 7]. By
virtue of their lower price, biosimilars have the potential
to reduce healthcare costs relative to reference biologics
[8–11], thereby increasing access to biologic drugs for
patients who require them.
CT-P13 (Remsima®, Inflectra®) is a biosimilar of refer-
ence infliximab (Remicade®), hereafter referred to as the
reference product (RP). It has been approved by the
European Medicines Agency for use in all the indica-
tions for which RP is licensed, including RA. CT-P13
and RP are the same in terms of their pharmaceutical
form, strength, composition and route of administration
[12]. Consequently, dosage and administration instruc-
tions for CT-P13 are the same as those for RP. Nonclini-
cal evaluations have shown that CT-P13 and RP are
comparable with regard to the potency of TNF
neutralization, the key mechanism of action of inflixi-
mab, in WEHI 164 cells [12]. A number of other in vitro
assays have also demonstrated the similarity of CT-P13
and RP in terms of levels of apoptosis and complement-
dependent cytotoxicity in a transmembrane TNF-
expressing Jurkat cell line, and of antibody-dependent
cellular cytotoxicity using peripheral blood mononuclear
cells or whole blood from patients with Crohn’s disease
[12, 13].
The PLANETRA (Programme evaLuating the Auto-
immune disease iNvEstigational drug cT-p13 in RA pa-
tients) study was performed to assess the equivalence in
efficacy of CT-P13 and RP treatment in patients with
active RA. The primary 30-week findings proved equiva-
lency in efficacy outcomes between CT-P13 and RP in
terms of American College of Rheumatology (ACR) re-
sponse (intent-to-treat population) [14]. Safety, pharma-
cokinetics (PK) and pharmacodynamics (PD) profiles
were also comparable between the two drugs. As re-
ported here, the PLANETRA study researchers also
evaluated the extended effects of CT-P13 compared with
RP in patients with active RA up to 54 weeks, includ-
ing efficacy, radiographic progression, immunogen-
icity, safety, PK and PD.
Methods
Full details of the methods of this study have been
reported previously [14].
Patients
Patients aged 18–75 years were included if they had
been diagnosed with RA according to the revised 1987
ACR classification criteria for ≥1 year before screening.
Active disease was defined as having at least six swollen
joints, at least six tender joints and at least two of the
following: morning stiffness for at least 45 minutes,
erythrocyte sedimentation rate (ESR) >28 mm/h or
serum C-reactive protein (CRP) concentration >2.0 mg/
dl. Eligible patients had not responded adequately to
MTX for ≥3 months and were required to have received
a stable MTX dose (12.5–25 mg/week) for ≥4 weeks be-
fore screening.
Study design and treatment
This randomized, double-blind, multicenter, multi-
national, parallel-group, prospective phase III study
(ClinicalTrials.gov identifier NCT01217086) was
performed at 100 study centers across 19 countries in
Europe, Asia, Latin America and the Middle East. Pa-
tients were randomly assigned (1:1 ratio) to receive 3
mg/kg of CT-P13 (CELLTRION Inc, Incheon, Republic
of Korea) or RP (Janssen Biotech Inc, Horsham, PA,
USA) via a 2-h intravenous infusion. Patients were
treated at weeks 0, 2 and 6 and then received a further
six infusions every 8 weeks until week 54. Patients were
premedicated with an antihistamine as needed. MTX
and folic acid were coadministered to all patients. The
study was conducted according to the Declaration of
Helsinki and International Committee on Harmonisation
Good Clinical Practice guidelines. The protocol was
approved by regulatory authorities and the ethics
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committees of each study site. All patients provided
written informed consent.
Study endpoints and assessments
Efficacy, PK, PD and safety parameters were evaluated
up to week 54. The primary endpoint of this study was
the ACR20 response rate at week 30. Equivalence of effi-
cacy according to ACR20 criteria was concluded if the
95 % confidence interval (CI) for the treatment differ-
ence was within ±15 %. Efficacy parameters were evalu-
ated at baseline and at weeks 14, 30 and 54. Eligible
patients were followed for ACR20, ACR50, ACR70, Dis-
ease Activity Score in 28 joints (DAS28), Simplified Dis-
ease Activity Index (SDAI), Clinical Disease Activity
Index (CDAI) and European League Against Rheuma-
tism (EULAR) response rate. Patient-reported outcomes
(PROs) were evaluated using patient assessment of pain
on the visual analogue scale (VAS), VAS patient global
assessment of disease activity, the Health Assessment
Questionnaire (HAQ) estimate of physical ability and
the Medical Outcomes Study Short Form Health Survey
(SF-36). To assess joint damage progression (JDP), ra-
diographs obtained at baseline and at week 54 were eval-
uated with the “paired review” method; this evaluation
was performed by two independent readers without
knowledge of the time point of the radiographs. Individ-
ual component scores for JDP were calculated according
to the van der Heijde modification of the Sharp scoring
system, and used the mean score of two readers [15].
With respect to immunogenicity, the proportion of pa-
tients positive for antidrug antibodies (ADAs) was evalu-
ated at screening and at weeks 14, 30 and 54 [14]. The
neutralizing activity of ADAs (NAbs) was also assessed
by a flow-through immunoassay method using the Gyros
immunoassay platform (Gyros AB, Uppsala, Sweden).
For safety, adverse events (AEs) and changes in labora-
tory parameters were monitored throughout the study.
A treatment-emergent AE (TEAE) was defined as any
event not present before exposure to study treatment or
an event that worsened in intensity or frequency after
exposure to study treatment. At each planned visit, pa-
tients were screened for tuberculosis (TB) by clinical
examination with careful history taking. For patients liv-
ing in countries with an increased TB prevalence, inter-
feron γ-release assay (IGRA; QuantiFERON-TB Gold-IT,
QIAGEN, Hilden, Germany) was rechecked at weeks 14,
30 and 54 to identify positive conversion from negative
results at baseline [14]. Latent TB was defined as a posi-
tive conversion of IGRA together with a negative exam-
ination on chest x-ray. Patients were monitored for
infusion-related reactions, including hypersensitivity and
anaphylactic reaction.
PK evaluations included mean maximum serum
drug concentration and mean minimum serum drug
concentration. PD evaluations included CRP and ESR.
Serum blood samples were obtained immediately before
dosing, at the end of the infusion and 1 h after the infu-
sion for PK assessments, and immediately before dosing
for PD assessments.
Post hoc efficacy endpoints included the proportion of
patients achieving ACR/EULAR remission by visit (Bool-
ean-based, defined as swollen joint count [SJC] and ten-
der joint count [TJC] less than or equal to one, CRP ≤1
mg/dl, and patient global VAS ≤1 using a 0–10 scale; or
index-based, defined as SDAI ≤3.3) and the proportion
of patients who had no radiographic progression in total
Sharp score (≤0 or ≤0.5 units of change from baseline).
Statistical analyses
Statistical analyses were performed using SAS software
version 9.1.3 or later (SAS Institute, Cary, NC, USA). Ef-
ficacy analyses were performed in the per-protocol (PP)
population, which included all randomly assigned pa-
tients who did not have any major protocol deviations,
using the as-observed method. The JDP analysis was
performed in the intent-to-treat population (ITT), which
included all randomly assigned patients. ACR response
rates were also evaluated in the ITT population, as well
as the PP population, using nonresponder imputation
(NRI) for missing values. Exact binomial analyses and
sensitivity analyses were performed for the ACR end-
points. Descriptive statistics were performed for DAS28,
SDAI, CDAI, EULAR response, JDP, PROs including pa-
tient assessment of pain using the VAS, patient assess-
ment of disease activity using the VAS, HAQ and SF-36.
EULAR response criteria were analyzed using a propor-
tional odds model stratified by region and CRP. Analysis
of DAS28 was by analysis of covariance (ANCOVA) with
treatment as a fixed effect and baseline DAS28, region
and CRP category as covariates. Additional analyses were
carried out for assessment of JDP, including patients
with missing data (incomplete images) at week 54. De-
tails of the methods have been reported previously [16].
Safety assessments were conducted in all patients who
received at least one part infusion of study drug (safety
population). The PK-PD population consisted of all pa-
tients who received either study drug during the 30-
week blinded study period and had at least one PK-PD
concentration data value.
Sensitivity analyses included ACR responses using a
last observation carried forward (LOCF) approach in the
ITT population; descriptive statistics of DAS28, SDAI,
CDAI and EULAR response; and PROs in the ITT popu-
lation. For post hoc efficacy endpoints, NRI was used for
the calculation of ACR/EULAR remission rates. Linear
interpolation or extrapolation was used to calculate the
proportion of patients who had no radiographic progres-
sion in total Sharp score.
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Results
Patient disposition and baseline characteristics
Of the 606 randomized patients, most (n = 455) were
treated up to week 54: 233 (77.2 %) of 302 with CT-P13
and 222 (73.0 %) of 304 with RP (Fig. 1). As has been
reported previously [14], baseline patient demographics
and disease characteristics were similar between the two
groups (Table 1).
Efficacy
Overall, efficacy results for CT-P13 up to week 54 were
generally comparable to those observed with RP. No
statistical differences were observed for any efficacy end-
point. The primary endpoint of PLANETRA (ACR20
response at week 30) was equivalent between the two
treatment groups [14]. The ACR20, ACR50 and ACR70
treatment responses were analogous between the two
treatment groups throughout the course of the study
(Fig. 2). At week 54 in the CT-P13 versus RP groups, the
ACR20, ACR50 and ACR70 responses in the PP popula-
tion were 74.7 % (168 of 225) versus 71.3 % (154 of 216),
43.6 % (98 of 225) versus 43.1 % (93 of 216) and 21.3 %
(48 of 225) versus 19.9 % (43 of 216), respectively. ACR
responses in the ITT population are shown in Additional
file 1 and were also similar between the two treatment
groups, regardless of the method of missing data imput-
ation (NRI or LOCF).
Disease activity as measured by DAS28-ESR, DAS28-
CRP, SDAI and CDAI decreased from baseline through
to week 54 in the PP population as well as in the ITT
population (Fig. 3a–d and Additional file 2A–D). For all
of these parameters, the reductions were comparable
between the CT-P13 and RP treatment groups. In the
CT-P13 group at week 54, the mean decreases from
baseline in DAS28-ESR, DAS28-CRP, SDAI and CDAI
scores were 2.4, 2.3, 26.3 and 25.7, respectively, in the
PP population. The respective mean values for RP were
2.4, 2.2, 24.6 and 24.0. There was no evidence of a differ-
ence between the two treatment groups in change from
baseline in DAS28-ESR or DAS28-CRP at each time
point at the 5 % level of significance (DAS28-ESR treat-
ment differences [95 % CIs] −0.11 [−0.31, 0.10] at week
14, −0.10 [−0.33, 0.13] at week 30 and −0.05 [−0.30,
0.19] at week 54; DAS28-CRP treatment differences
−0.15 [−0.34, 0.05] at week 14, −0.06 [−0.27, 0.16] at
week 30 and −0.07 [−0.30, 0.17] at week 54 in the PP
population). Likewise, the proportion of patients with a
good and moderate EULAR response to treatment was
similar between the two treatment groups throughout the
study in both the PP and the ITT populations (EULAR
[ESR] and EULAR [CRP]) (Fig. 3e–f and Additional file
2E–F). With CT-P13 at week 54, 86.0 % (191 of 222) and
87.4 % (194 of 222) of patients had a moderate or good
response according to EULAR (ESR) and EULAR (CRP)
criteria, respectively, in the PP population. Respective
values for RP were 81.2 % (177 of 218) and 82.5 % (179 of
217), respectively, in the PP population.
In terms of PROs (Table 2 and Additional file 3), mean
decreases in VAS score for patient assessment of pain
from baseline were similar between the two treatment
groups in both the PP population and the ITT popula-
tion. Mean baseline VAS scores for patient assessment
of pain for CT-P13 and RP, respectively, were 65.7 and
65.5 in the PP population. Respective mean decreases
Fig. 1 Patient disposition. A total of 606 patients were randomized into either the CT-P13 group (n = 302) or the RP group (n = 304). A
total of 151 patients were withdrawn for the stated reasons. The first patient was screened in November 2010, and the last patient visit
was in July 2012. RP reference product (i.e., reference infliximab)
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from baseline were 29.6 versus 27.1 at week 14, 29.5
versus 27.7 at week 30 and 30.2 versus 28.4 at week 54.
For patient global assessment of disease activity, mean
decreases from baseline were also similar in both groups.
The respective mean baseline VAS scores for patient glo-
bal assessment of disease activity for CT-P13 and RP
were 65.1 versus 65.3 in the PP population. Respective
mean decreases from baseline were 29.5 versus 25.5 at
week 14, 28.1 versus 26.9 at week 30 and 30.3 versus
26.6 at week 54. Mean score for the HAQ estimate of
physical ability decreased from baseline at weeks 14, 30
and 54 in each treatment arm. Mean decreases from
baseline were again similar in both groups. The respect-
ive mean baseline HAQ estimate of physical ability for
CT-P13 and RP was 1.61 versus 1.54 in the PP popula-
tion. The respective mean decreases from baseline were
0.59 versus 0.50 at week 14, 0.60 versus 0.51 at week 30
and 0.60 versus 0.52 at week 54.
Throughout the study, mean SF-36 score increased
from baseline to week 54 in both groups. Scores were
Table 1 Baseline patient demographics and disease characteristics
CT-P13 3 mg/kg (n = 302) RP 3 mg/kg (n = 304) Total (N = 606)
Age, median, years (range) 50 (18–75) 50 (21–74) 50 (18–75)
Sex, n (%)
Female 245 (81.1) 256 (84.2) 501 (82.7)
Male 57 (18.9) 48 (15.8) 105 (17.3)
Ethnicity, n (%)
Asian 34 (11.3) 37 (12.2) 71 (11.7)
Black 2 (0.7) 1 (0.3) 3 (0.5)
White 220 (72.8) 222 (73.0) 442 (72.9)
Other 46 (15.2) 44 (14.5) 90 (14.9)
Height, cm, median (range) 162.3 (144.0–186.0) 162.0 (124.0–190.0) 162.0 (124.0–190.0)
Weight, kg, median (range) 69.0 (36.5–134.0) 68.0 (36.0–136.0) 68.6 (36.0–136.0)
BMI, kg/m2, median (range) 26.3 (13.9–49.8) 25.4 (15.0–53.1) 25.9 (13.9–53.1)
Anti-CCP antibody-positive, n (%) 228 (75.5) 233 (76.6) 461 (76.1)
IgA RF-positive, n (%) 131 (43.4) 134 (44.1) 265 (43.7)
IgM RF-positive, n (%) 225 (74.5) 220 (72.4) 445 (73.4)
IgG RF-positive, n (%) 173 (57.3) 171 (56.3) 344 (56.8)
Joint count
TJC, 68 joints 25.6 ± 13.9 24.0 ± 12.9 24.8 ± 13.4
SJC, 66 joints 16.2 ± 8.7 15.2 ± 8.3 15.7 ± 8.5
TJC, 28 joints 15.9 ± 6.4 15.1 ± 6.1 15.5 ± 6.2
SJC, 28 joints 12.0 ± 4.9 11.2 ± 4.7 11.6 ± 4.8
Duration of prior MTX therapy, weeks 97.7 ± 141.2 89.4 ± 96.5 93.6 ± 120.8
MTX dose, mg 15.6 ± 3.1 15.6 ± 3.2 15.6 ± 3.1
CDAI 40.9 ± 11.5 39.3 ± 11.1 40.1 ± 11.3
SDAI 42.8 ± 11.9 41.2 ± 11.7 42.0 ± 11.8
CRP, mg/dl 1.9 ± 2.5 1.9 ± 2.2 1.9 ± 2.4
ESR, mm/h 46.6 ± 22.4 48.5 ± 22.6 47.5 ± 22.5
DAS28-CRP 5.9 ± 0.8 5.8 ± 0.9 5.8 ± 0.9
HAQ 1.6 ± 0.6 1.6 ± 0.6 1.6 ± 0.6
Patient assessment of pain 65.9 ± 17.4 65.5 ± 17.2 65.7 ± 17.3
Patient global assessment of disease activity 65.7 ± 17.2 65.4 ± 17.0 65.5 ± 17.1
Physician global assessment of disease activity 64.7 ± 14.3 65.0 ± 13.5 64.8 ± 13.9
BMI body mass index, CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, ESR
erythrocyte sedimentation rate, HAQ Health Assessment Questionnaire, Ig immunoglobulin, MTX methotrexate, RF rheumatoid factor, RP reference product (i.e.,
reference infliximab), SD standard deviation, SDAI Simplified Disease Activity Index, SJC swollen joint count, TJC tender joint count
Except where indicated otherwise, values are mean ± SD
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similar between CT-P13 and RP groups for all compo-
nents of the SF-36. For the physical component sum-
mary, the mean increase from baseline to week 54 was
7.6 and 6.6 with CT-P13 and RP, respectively, in the PP
population. For the mental component summary, the
mean increase from baseline to week 54 was 7.1 and 6.9
with CT-P13 and RP, respectively, in the PP population.
The proportion of patients achieving remission was
similar between groups throughout the study in both
Boolean-based and index-based (SDAI) ACR/EULAR
remission criteria in the ITT population using the NRI
approach (Fig. 4).
Radiologic progression
In total, 336 patients had radiographs at both baseline
and week 54 and were eligible for assessment of JDP.
Mean total Sharp scores at baseline were 68.3 in the CT-
P13 group and 64.8 in the RP group. The mean change
from baseline to week 54 in JDP was similar between the
CT-P13 and RP treatment groups with respect to total
Sharp score (1.0 ± 6.3 versus 0.6 ± 5.6, p = 0.5463), joint
space narrowing score (0.4 ± 4.2 versus 0.7 ± 4.0, p =
0.4852) and erosion score (0.7 ± 3.9 versus 0.0 ± 3.4, p =
0.0795). Changes in total Sharp score from baseline to
week 54 were 1.3 ± 9.3 and 0.7 ± 7.0 for CT-P13 and RP
(p = 0.3171), respectively, when ANCOVA was used.
There was no impact of the choice of imputation
(ANCOVA, simple linear extrapolation, or no missing
data imputation).
The proportion of patients who had no radiographic
progression in total Sharp score was similar in both
groups (≤0 units of change from baseline: 51.7 % [153 of
296] and 51.4 % [151 of 294] in the CT-P13 and RP
groups, respectively [p = 1.0000]; ≤0.5 units of change
from baseline: 58.1 % [172 of 296] and 57.8 % [170 of
294] [p = 1.0000], respectively, with linear interpolation
or extrapolation).
Immunogenicity
The proportion of patients positive for ADAs at week 54
was similar between the two treatment groups: 124 (41.1
%) and 108 (36.0 %) in the CT-P13 and RP groups, re-
spectively. In general, almost all patients with a positive
ADA result were also positive for NAbs.
Safety
Among 606 patients randomized (302 and 304 patients
in the CT-P13 and RP groups, respectively), 300 and 302
patients initiated study treatment. Owing to incorrect
kits’ being dispensed, two patients in the RP group re-
ceived one dose of CT-P13. Therefore, the safety popula-
tion comprised 302 patients in the CT-P13 group and
300 in the RP group.
In general, CT-P13 was well tolerated and had a safety
profile similar to that of RP. Overall, TEAEs were re-
ported for 213 patients (70.5 %) in the CT-P13 group
and 211 patients (70.3 %) in the RP group. TEAEs con-
sidered to be related to treatment occurred in 132 pa-
tients (43.7 %) in the CT-P13 group and 135 patients
(45.0 %) in the RP group. The most frequently reported
drug-related TEAEs (Table 3), occurring in at least nine
patients in either treatment arm, were as follows in
order of frequency: (1) for CT-P13, infusion-related reac-
tion, upper respiratory tract infection, latent TB, abnor-
mal liver function test, lower respiratory tract infection
and urinary tract infection; and (2) for RP, infusion-
related reaction, latent TB, upper respiratory tract infec-
tion, abnormal liver function test, urinary tract infection
Fig. 2 American College of Rheumatology (ACR) response rates over time in the per-protocol population, with nonresponder imputation approach.
To estimate the difference in proportions between the two treatment groups, we used the exact binomial test. ACR20, ACR50 and ACR70 denote the
ACR 20 %, 50 % and 70 % improvement criteria, respectively. CI confidence interval, RP reference product (i.e., reference infliximab)
Yoo et al. Arthritis Research & Therapy  (2016) 18:82 Page 6 of 12
and lower respiratory tract infection. In the CT-P13 and
RP treatment groups, infusion-related reactions were re-
ported for 30 patients (9.9 %) and 43 patients (14.3 %),
respectively.
Active TB was reported in three patients (1 %) in the
CT-P13 group and no patients in the RP group. Of the
three patients with active TB, one patient was diagnosed
with TB based on clinical judgment alone rather than on
a positive identification of Mycobacterium. The propor-
tion of patients who had a negative IGRA result at
screening followed by a positive IGRA result during
study drug exposure was similar (39 [12.9 %] and 38
[12.7 %] patients in the CT-P13 and RP groups, respect-
ively). Among these, 28 (9.3 %) and 26 (8.7 %) patients,
respectively, were reported as having a latent TB TEAE
based on the judgment of investigators, and 24 (7.9 %)
Fig. 3 Changes in efficacy parameters over time with CT-P13 and RP in the per-protocol population. a Disease activity based on DAS28-ESR. b Disease
activity based on DAS28-CRP. c Disease activity based on SDAI. d Disease activity based on CDAI. e EULAR response criteria based on DAS28-ESR score.
f EULAR response criteria based on DAS28-CRP score. *Proportional odds model with EULAR as response, treatment as a fixed effect, and region and CRP
category as covariates. An odds ratio >1 implied that a patient who received CT-P13 had a higher likelihood of EULAR response than a patient who
received RP. The proportional odds assumption implied that the relationship between each pair of outcome responses was the same. CDAI Clinical
Disease Activity Index, CI confidence interval, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, EULAR
European League Against Rheumatism, RP reference product (i.e., reference infliximab), SD standard deviation, SDAI Simplified Disease Activity Index
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and 20 (6.7 %) patients, respectively, started TB prophy-
laxis with isoniazid.
The majority of TEAEs were mild to moderate
in severity and did not lead to discontinuation.
Treatment-emergent serious AEs were reported in 42
patients (13.9 %) in the CT-P13 group, and 31
patients (10.3 %) in the RP group. Among them, 23
patients (7.6 %) in the CT-P13 group and 14 patients
(4.7 %) in the RP group were considered to have
events related to treatment (Additional file 4). The
Table 2 Improvement in patient-reported outcomes with CT-P13 and RP in the per-protocol population
CT-P13 (3 mg/kg) RP (3 mg/kg)
Time point n Actual result (mean ± SD) Change from baseline (mean ± SD) n Actual result (mean ± SD) Change from baseline (mean ± SD)
VAS score for the patient assessment of pain
Baseline 248 65.7 ± 17.8 – 251 65.5 ± 17.7 –
Week 14 248 36.1 ± 21.4 −29.6 ± 23.3 250 38.3 ± 22.2 −27.1 ± 23.1
Week 30 248 36.2 ± 22.9 −29.5 ± 25.6 250 37.7 ± 23.6 −27.7 ± 24.9
Week 54 226 35.0 ± 21.2 −30.2 ± 23.8 220 37.4 ± 24.7 −28.4 ± 26.9
VAS score for the patient global assessment of disease activity
Baseline 248 65.1 ± 17.5 – 251 65.3 ± 17.3 –
Week 14 248 35.6 ± 21.1 −29.5 ± 22.1 249 39.7 ± 22.5 −25.5 ± 24.4
Week 30 247 37.0 ± 22.3 −28.1 ± 25.9 250 38.4 ± 23.4 −26.9 ± 25.5
Week 54 225 34.9 ± 20.7 −30.3 ± 24.3 220 38.7 ± 25.3 −26.6 ± 27.8
HAQ estimate of physical ability
Baseline 248 1.61 ± 0.56 – 251 1.54 ± 0.58 –
Week 14 248 1.02 ± 0.62 −0.59 ± 0.55 251 1.04 ± 0.64 −0.50 ± 0.50
Week 30 248 1.01 ± 0.64 −0.60 ± 0.60 251 1.03 ± 0.66 −0.51 ± 0.56
Week 54 226 0.99 ± 0.61 −0.60 ± 0.61 220 1.02 ± 0.64 −0.52 ± 0.59
SF-36 score (physical component summary)
Baseline 247 31.4 ± 6.1 – 251 31.8 ± 7.2 –
Week 14 247 38.9 ± 7.6 7.5 ± 7.1 251 37.6 ± 7.9 5.8 ± 6.8
Week 30 248 38.6 ± 7.9 7.1 ± 7.9 250 38.3 ± 8.0 6.5 ± 7.6
Week 54 226 39.2 ± 7.5 7.6 ± 8.1 220 38.6 ± 8.7 6.6 ± 8.4
SF-36 score (mental component summary)
Baseline 247 36.8 ± 10.4 – 251 38.4 ± 11.3 –
Week 14 247 43.4 ± 10.7 6.6 ± 10.2 251 44.9 ± 9.6 6.5 ± 10.4
Week 30 248 44.0 ± 10.2 7.1 ± 10.0 251 45.0 ± 10.3 6.6 ± 10.4
Week 54 226 43.9 ± 9.9 7.1 ± 10.1 220 45.1 ± 10.0 6.9 ± 11.2
HAQ Health Assessment Questionnaire, RP reference product (i.e., reference infliximab), SD standard deviation, SF-36 Medical Outcomes Study Short Form Health
Survey, VAS visual analogue scale (mm)
Fig. 4 Proportion of patients with ACR/EULAR remission in the intent-to-treat population, with nonresponder imputation approach. a ACR/EULAR
remission by Boolean-based criterion. b ACR/EULAR remission by index-based criterion (SDAI). p value was calculated using Fisher’s exact test.
ACR American College of Rheumatology, EULAR European League Against Rheumatism, RP reference product (i.e., reference infliximab), SDAI Simplified
Disease Activity Index
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proportion of patients who discontinued study treat-
ment due to TEAEs was similar between the two
groups: 33 patients (10.9 %) in the CT-P13 group and
47 patients (15.7 %) in the RP group; 29 (9.6 %) and
37 (12.3 %) patients, respectively, discontinued due to
TEAEs considered to be related to treatment.
Treatment-related events that caused discontinuation
and occurred in more than one patient were infusion-
related reaction (n = 14 [4.6 %]), TB (n = 3 [1.0 %]),
anemia (n = 2 [0.7 %]), and abnormal liver function
test (n = 2 [0.7 %]) in the CT-P13 group and infusion-
related reaction (n = 17 [5.7 %]) and latent TB (n = 5
[1.7 %]) in the RP group. One death in the RP group
was reported during the study. The cause was un-
known and not considered to be related to the study
treatment.
Pharmacokinetics and pharmacodynamics
The PK and PD findings were highly comparable
between the CT-P13 and RP groups. In the overall PK
patient population, serum drug concentrations were
similar throughout the study in the CT-P13 and RP
groups (Fig. 5). In terms of PD, mean CRP and ESR
levels decreased from baseline at all time points (weeks
14, 30 and 54). Respective mean decreases were similar
in the CT-P13 and RP groups at week 54 for both CRP
(0.67 ± 2.17 and 0.66 ± 2.66) and ESR (12.3 ± 22.13 and
15.2 ± 21.89).
Discussion
The 54-week findings from this randomized, double-
blind, multicenter, multinational, parallel-group, pro-
spective phase III study confirm those previously
Table 3 Treatment-related adverse events reported in at least 1 % of total patients
CT-P13 (n = 302) RP (n = 300) Total CT-P13 + RP (n = 602)
Infusion-related reaction 30 (9.9) 43 (14.3) 73 (12.1)
Latent TB 22 (7.3) 20 (6.7) 42 (7.0)
Upper respiratory tract infection 23 (7.6) 14 (4.7) 37 (6.1)
Abnormal liver function test 22 (7.3) 14 (4.7) 36 (6.0)
Urinary tract infection 9 (3.0) 11 (3.7) 20 (3.3)
Lower respiratory tract infection 10 (3.3) 9 (3.0) 19 (3.2)
Flare in RA activity 7 (2.3) 5 (1.7) 12 (2.0)
Herpes virus infection 3 (1.0) 7 (2.3) 10 (1.7)
Anemia 4 (1.3) 5 (1.7) 9 (1.5)
Headache 4 (1.3) 5 (1.7) 9 (1.5)
Rash 2 (0.7) 4 (1.3) 6 (1.0)
Pyrexia 1 (0.3) 5 (1.7) 6 (1.0)
RA rheumatoid arthritis, RP reference product (i.e. reference infliximab), TB tuberculosis
Data are presented as count (percentage)
Fig. 5 Serum concentrations of infliximab (mean ± SD) versus time in the CT-P13 and RP treatment groups in the pharmacokinetic population. RP
reference product (i.e., reference infliximab), SD standard deviation
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reported at week 30 [14]. The results show that CT-
P13 (3 mg/kg) and RP (3 mg/kg) are comparable in
terms of efficacy, immunogenicity, safety and PK-PD
in patients with active RA not responding adequately
to MTX.
As previously reported for this study, the ACR20
response at week 30 (primary study endpoint) was
equivalent for CT-P13 and RP, as the 95 % CIs for
treatment difference were within the predefined mar-
gins for equivalence [14]. Similarly, at week 54, the
efficacy of CT-P13 and RP was highly comparable
across a broad range of measures of disease activity,
including ACR responses and DAS28-ESR, DAS28-
CRP, SDAI and CDAI, as well as PROs, including
VAS scores for the patient assessment of pain and
the patient global assessment of disease activity, HAQ
scores and SF-36 scores.
Regarding the assessment of JDP, the handling of miss-
ing data and use of appropriate statistical techniques are
important when analyzing radiographic results of a clin-
ical trial. If several different methods of analysis give
comparable results, the credibility of the data is in-
creased [15]. CT-P13 showed comparable results when
analyzed using either of two different missing data impu-
tations or when missing data were excluded. The pro-
portion of patients with no radiographic progression in
total Sharp score was also similar in the two groups
when using linear interpolation or extrapolation.
While there are limitations associated with comparing
data across studies, the ACR responses we observed at
week 54 were generally in the range of those reported in
two previous randomized studies with RP in similar pa-
tient populations [16, 17]. For example, between weeks
52 and 54, ACR20 responses with RP ranged from 42 %
to 56 % in these historical published studies (ITT ana-
lyses) [16, 17]. The ACR20 associated with CT-P13 in
the present study was 57 % at week 54 (ITT analysis). In
line with findings at week 0 [14], PK-PD parameters
remained comparable between the CT-P13 and RP treat-
ment groups at week 54. Serum drug concentrations and
decreases in CRP and ESR levels were similar with both
CT-P13 and RP throughout the study. These data are
supported by the findings from the PLANETAS study
[18], which also showed that CT-P13 and RP have simi-
lar effects on efficacy and PK-PD. The safety profile of
CT-P13 observed in the present analysis was also similar
to that of RP, and both agents were shown to be well tol-
erated through to week 54. The safety results were gen-
erally aligned with the findings from previous
randomized trials of RP up to week 54 in patients with
RA [16, 17, 19].
Data from the present study and a similar trial in pa-
tients with ankylosing spondylitis (PLANETAS) [18, 20]
have shown that CT-P13 and RP possess comparable
clinical efficacy, PK-PD and safety when used for over 1
year. Assuming that the biosimilar is priced less than the
reference biologic—and in the European Union, biosimi-
lars are generally approximately 30 % less expensive than
reference products [21]—CT-P13 may prove to be a cost-
effective alternative to infliximab RP. In this regard, a
budget impact analysis recently assessed the potential ef-
fects of introducing CT-P13 for the treatment of RA in six
central and eastern European countries. This analysis esti-
mated savings of €20.8 million over 3 years if 80 % of pa-
tients taking RP switched to CT-P13, on the assumption
that the price of CT-P13 is 75 % that of the RP [22]. In
other countries, such as Norway and Denmark, biosimilar
infliximab is recommended by tender systems and, indeed,
it has rapidly increased market share in Norway due to
the large difference in price between the reference product
and the biosimilar [23]. The National Institute for Health
and Care Excellence (NICE) in the United Kingdom chan-
ged its position on the use of infliximab for the treatment
of ankylosing spondylitis by recommending the least ex-
pensive drug [24]. They also recommend using the least
expensive infliximab for RA treatment [25]. The increas-
ing use of biosimilars in the treatment of various inflam-
matory diseases may enhance reductions or discounts of
the originator biologic’s price [21, 26]. This trend may fi-
nally increase accessibility to biologics and reduce total
cost further.
The efficacy and safety of CT-P13 up to 102 weeks is be-
ing assessed in an extension of the present study, which is
also evaluating switching treatment from RP to CT-P13 in
patients with RA. The findings from the extension may
support the longer-term efficacy and safety of CT-P13.
The main limitation of the present analysis is that
the study sample size was calculated to analyze the
primary endpoint at 30 weeks. Therefore, the pro-
spective longer-term findings presented here at 54
weeks were not a key consideration when calculating
the sample size.
Conclusions
This randomized, multinational study in patients with
active RA inadequately responding to MTX demon-
strated that CT-P13 had comparable efficacy, im-
munogenicity and PK-PD to RP up to week 54.
Additionally, CT-P13 was well tolerated, with a safety
profile comparable to that of RP up to week 54.
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Additional file 1: (A) American College of Rheumatology (ACR) response
rates over time in the intent-to-treat population, with NRI approach. (B).
American College of Rheumatology (ACR) response rates over time in the
intent-to-treat population, with LOCF approach. To estimate the difference
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binomial test. ACR20, ACR50 and ACR70 denote the ACR 20 %, 50 %
and 70 % improvement criteria, respectively. ACR, American College
of Rheumatology; CI, confidence interval; LOCF, last observation
carried forward; NRI, nonresponder imputation; RP, reference product
(i.e. reference infliximab). (TIF 1024 kb)
Additional file 2: Changes in efficacy parameters over time with CT-P13
and RP in the intent-to-treat population. (A) Disease activity based on
DAS28-ESR; (B) Disease activity based on DAS28-CRP; (C) Disease activity
based on SDAI; (D) Disease activity based on CDAI; (E) EULAR response
criteria based on DAS28-ESR score; (F) EULAR response criteria based on
DAS28-CRP score. *Proportional odds model with EULAR as response,
treatment as a fixed effect, and region and CRP category as covariates. An
odds ratio >1 implied that a patient who received CT-P13 had a higher
likelihood of EULAR response than a patient who received RP. The
proportional odds assumption implied that the relationship between each
pair of outcome response was the same. CDAI, Clinical Disease Activity Index;
CI, confidence interval; CRP, C-reactive protein; DAS28, Disease Activity Score
in 28 joints; ESR, erythrocyte sedimentation rate; EULAR, European League
Against Rheumatism; RP, reference product (i.e., reference infliximab); SD,
standard deviation; SDAI, Simplified Disease Activity Index. (TIF 1420 kb)
Additional file 3: Improvement in patient-reported outcomes with CT-P13
and RP in the intent-to-treat population. (DOC 52 kb)
Additional file 4: Overview of treatment-related serious adverse events
occurring by severity (n [%]). (DOC 49 kb)
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